Andrew Holden, MBChB

Shape Memory Medical Initiates First-in-Human FLAGSHIP Study of False Lumen Embolization System

April 1, 2026—Shape Memory Medical has announced the first patient enrollments in the FLAGSHIP study, a prospective single-arm open-label first-in-human trial evaluating its investigational False Lumen Embolization (FLE) System for treatment of aortic dissection.

Shape Memory Medical’s AAA-SHAPE Pivotal Trial Commences

June 3, 2024—Shape Memory Medical Inc. announced that the first patient was treated in the AAA-SHAPE pivotal trial.

Medtronic’s In.Pact AV DCB Evaluated at 60 Months in the IN.PACT AV Access Study

May 6, 2024—The IN.PACT AV Access randomized controlled trial continues to compare Medtronic’s In.Pact AV drug-coated balloon (DCB) to standard percutaneous transluminal angioplasty (PTA) in patients with de novo or nonstented restenotic arteriovenous (AV) fistula lesions.

Surmodics Sundance Sirolimus DCB Evaluated in 24-Month SWING Data

November 16, 2023—Surmodics, Inc. announced 24-month data from the SWING trial, a first-in-human study of the company’s Sundance sirolimus drug-coated balloon (DCB).

Professor Roger M. Greenhalgh, MD, 1941–2023

The Charing Cross (CX) International Symposium announced the passing of its founder, Professor Roger Greenhalgh, MD, Emeritus Professor of Surgery at Imperial College in London, and head of the Vascular Surgery Research Group.

Shape Memory’s Impede-FX RapidFill Will Be Studied in AAA-SHAPE Pivotal Trial

September 7, 2023—Shape Memory Medical Inc., a developer of custom shape memory polymers for endovascular applications, announced that the FDA granted an investigational device exemption (IDE) for the Impede-FX RapidFill device.

Shape Memory Medical’s Impede Embolization Plug Evaluated in Published Safety Study

May 30, 2023—Shape Memory Medical Inc., which develops shape memory polymer for peripheral and neurovascular applications, announced the publication of results from the company’s safety study of the Impede embolization plug in peripheral vascular embolization.

Medtronic’s IN.PACT AV Access Study Subanalysis Data Presented

April 26, 2023—Medtronic announced the presentation of additional 36-month data from a subanalysis of the IN.PACT AV Access study, as well as 48-month vital status outcomes.

Cagent Vascular’s Serranator PTA Catheter Compared to POBA in Subanalysis of PRELUDE BTK Study

January 31, 2023—Cagent Vascular announced the results of a comparative subanalysis of the PRELUDE-BTK study versus plain old balloon angioplasty (POBA) in the treatment of below-the-knee (BTK) peripheral artery disease (PAD).

Efemoral Medical’s EVSS Device Development Supported by New Funding

December 13, 2022—Efemoral Medical, a developer of next-generation bioresorbable solutions to treat patients with vascular disease, announced the closing of its $4.9M preferred Series A1 round.

Fluidx Completes Follow-Up in Multicenter Study of GPX Liquid Embolic Agent

October 6, 2022—Fluidx Medical announced the completion of follow-up in its multicenter clinical trial examining the broad application of the company’s new GPX liquid embolic agent for arterial and venous embolization.

Fluidx Completes Enrollment in Trial for GPX Embolic Device

September 1, 2022—Fluidx Medical announced the completion of enrollment in a trial for its GPX embolic device.

Shape Memory Medical Completes Enrollment in AAA-SHAPE EFS, Evaluating Impede-FX RapidFill Device

August 29, 2022—Shape Memory Medical Inc. announced the completion of patient enrollment in AAA-SHAPE, a prospective multicenter early feasibility safety study of the Impede-FX RapidFill device when used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair (EVAR).

Medtronic’s In.Pact AV DCB Compared to PTA at 36 Months in IN.PACT AV Access Study

April 27, 2022—Medtronic announced the presentation of new 36-month data from the randomized controlled IN.PACT AV Access study comparing the company’s In.Pact AV drug-coated balloon (DCB) to percutaneous transluminal angioplasty (PTA) in patients with de novo or nonstented restenotic arteriovenous (AV) fistula lesions.

Fluidx Reports Use of GPX Embolic Device in Challenging Tumor Case

January 20, 2022—Fluidx Medical Technology, a Salt Lake City, Utah–based company that is developing the GPX embolic device, announced that the GPX continues to be evaluated in a multicenter clinical trial.

Medtronic’s In.Pact AV and In.Pact Admiral Devices Evaluated in Subset Data Presented at CIRSE

September 29, 2021—Medtronic announced the presentation of new subset data for its In.Pact AV paclitaxel drug-coated balloon (DCB) for arteriovenous (AV) access maintenance and for its In.Pact Admiral paclitaxel-coated percutaneous transluminal angioplasty (PTA) catheter.

Shape Memory Medical’s Impede-FX RapidFill Device Evaluated in AAA-SHAPE Netherlands Study

August 24, 2021—Shape Memory Medical Inc. announced the initiation of AAA-SHAPE Netherlands, the company’s prospective, multicenter, early feasibility study of its Impede-FX RapidFill device used for abdominal aortic aneurysm (AAA) sac management during elective endovascular aneurysm repair (EVAR).

2-Year Results Presented From Medtronic’s IN.PACT AV Access Trial

April 20, 2021—Medtronic announced that the safety and effectiveness results through 24 months for the IN.PACT AV Access clinical study were presented virtually at the 2021 Charing Cross Symposium.

PRELUDE-BTK Study Results Presented for Cagent Vascular’s Serranator Device

February 1, 2021—Cagent Vascular announced results of its PRELUDE-BTK study, a prospective, single-arm, multicenter feasibility study to show the safety and efficacy of percutaneous transluminal angioplasty (PTA) in below-the-knee (BTK) lesions with the company’s Serranator technology.

First-In-Human Study Begins for the Bioresorbable Efemoral Vascular Scaffold System

December 14, 2020—Efemoral Medical announced the first-in-human (FIH) use of the company’s bioresorbable, sirolimus-eluting Efemoral vascular scaffold system (EVSS) with FlexStep technology, which is designed to treat peripheral artery disease (PAD) in a broad range of patients.